Key Points
- Fred Aslan sold 6,375 Artiva shares on Nov. 17 at an average price of $3.38 for $21,547.50, lowering his stake by 1.82% to 343,999 shares; he also sold 25,500 shares on Oct. 17 at $6.00 ($153,000).
- Artiva (NASDAQ:ARTV) has a market cap of about $86.2M, a 52-week range of $1.47–$13.19, recently reported Q3 EPS of -$0.88 (beating estimates), and carries a consensus analyst rating of Moderate Buy with a $19 price target.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 6,375 shares of the firm's stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $3.38, for a total value of $21,547.50. Following the completion of the sale, the chief executive officer directly owned 343,999 shares of the company's stock, valued at $1,162,716.62. The trade was a 1.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Fred Aslan also recently made the following trade(s):
- On Friday, October 17th, Fred Aslan sold 25,500 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $6.00, for a total value of $153,000.00.
Artiva Biotherapeutics Stock Performance
NASDAQ:ARTV opened at $3.51 on Tuesday. The firm has a market capitalization of $86.17 million, a PE ratio of -1.34 and a beta of 3.04. The stock's fifty day moving average is $3.38 and its 200 day moving average is $2.70. Artiva Biotherapeutics, Inc. has a fifty-two week low of $1.47 and a fifty-two week high of $13.19.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. Equities analysts forecast that Artiva Biotherapeutics, Inc. will post -4.95 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of ARTV. Charles Schwab Investment Management Inc. grew its stake in Artiva Biotherapeutics by 26.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company's stock worth $165,000 after purchasing an additional 11,355 shares in the last quarter. Nuveen LLC purchased a new position in shares of Artiva Biotherapeutics during the first quarter valued at $144,000. Ground Swell Capital LLC purchased a new position in shares of Artiva Biotherapeutics during the second quarter valued at $38,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $48,000. Finally, Marshall Wace LLP purchased a new stake in Artiva Biotherapeutics in the second quarter worth about $79,000.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. Needham & Company LLC reiterated a "buy" rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a report on Friday, October 17th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research note on Thursday, October 30th. Wedbush raised their price target on Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an "outperform" rating in a research note on Friday, October 17th. Finally, HC Wainwright boosted their price objective on Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a "buy" rating in a report on Wednesday, November 12th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $19.00.
Read Our Latest Report on ARTV
About Artiva Biotherapeutics
(
Get Free Report)
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
